magicmine
- Insmed (NASDAQ:INSM) said it plans to submit a New Drug Application to the U.S. FDA for brensocatib as a treatment for the chronic lung condition bronchiectasis in Q4.
- The decision follows additional positive results from the phase 3 ASPEN study.
- In late May, the company announced the candidate met its primary endpoint.
- The new 52-week forced expiratory volume over one second (FEV1) data indicates that brensocatib is associated with significantly less decline in lung function compared to placebo.